Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
Identifieur interne : 005660 ( Main/Exploration ); précédent : 005659; suivant : 005661Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
Auteurs : L. Verhagen Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; D. De Jong [États-Unis] ; M. M. Mouradian [États-Unis] ; Chase [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1996-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Agonist, Antagonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Carbidopa (adverse effects), Carbidopa (therapeutic use), Chemotherapy, D1 Dopamine receptor, D1agonist, D2 Dopamine receptor, D2antagonist, Dopamine Agonists (administration & dosage), Dopamine Agonists (therapeutic use), Dopamine Antagonists (adverse effects), Dopamine Antagonists (therapeutic use), Dopamine D2 Receptor Antagonists, Double-Blind Method, Drug Therapy, Combination, Dyskinesias, Ergoline derivatives, Ergolines (adverse effects), Ergolines (therapeutic use), FCE 23884, Female, Human, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D1 (physiology), Receptors, Dopamine D2 (physiology), Treatment, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Dopamine Agonists.
- chemical , adverse effects : Antiparkinson Agents, Carbidopa, Dopamine Antagonists, Ergolines, Levodopa.
- chemical , drug effects : Receptors, Dopamine D1.
- chemical , physiology : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Dopamine Agonists, Dopamine Antagonists, Ergolines, Levodopa.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Dopamine D2 Receptor Antagonists, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
The ergoline derivative FCE 23884 acts as a dopamine D1 agonist in untreated parkinsonian animals and as a D2 antagonist in animals whose dopamine system is intact or levodopa treated. To evaluate whether this dual action might benefit patients with Parkinson's disease (PD) who have developed levodopa‐induced dyskinesias, the motor effects of FCE 23884 were examined in seven such individuals using a double‐blind, placebo‐controlled design. At doses up to the maximum tolerated dose (3.5 ± 0.5 mg), FCE 23884 monotherapy did not affect parkinsonian severity. On the other hand, coadministration of FCE 23884 with a mildly dyskinetic dose of levodopa, infused intravenously under steady‐state conditions, reduced the antiparkinson response by 54 ± 19% and tended to diminish dyskinesia severity. The results thus fail to suggest any useful role for FCE 23884 in the symptomatic treatment of PD. Although D2 receptor blockade provided by FCE 23884 antgonizes both the antiparkinson and dyskinesigenic responses to levodopa, the degree of D1 receptor stimulation appears insufficient to ameliorate parkinsonian symptomatology.
Url:
DOI: 10.1002/mds.870110307
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002C54
- to stream Istex, to step Curation: 002C54
- to stream Istex, to step Checkpoint: 003B62
- to stream PubMed, to step Corpus: 004842
- to stream PubMed, to step Curation: 004842
- to stream PubMed, to step Checkpoint: 004834
- to stream Ncbi, to step Merge: 004A93
- to stream Ncbi, to step Curation: 004A93
- to stream Ncbi, to step Checkpoint: 004A93
- to stream Main, to step Merge: 008766
- to stream PascalFrancis, to step Corpus: 003394
- to stream PascalFrancis, to step Curation: 003430
- to stream PascalFrancis, to step Checkpoint: 003377
- to stream Main, to step Merge: 008909
- to stream Main, to step Curation: 005660
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease</title><author><name sortKey="Metman, L Verhagen" sort="Metman, L Verhagen" uniqKey="Metman L" first="L. Verhagen" last="Metman">L. Verhagen Metman</name></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name></author><author><name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name></author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:856FE7AA63A3BA4C2A33C0FBCD7FB272518A1A6D</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/mds.870110307</idno><idno type="url">https://api.istex.fr/document/856FE7AA63A3BA4C2A33C0FBCD7FB272518A1A6D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002C54</idno><idno type="wicri:Area/Istex/Curation">002C54</idno><idno type="wicri:Area/Istex/Checkpoint">003B62</idno><idno type="wicri:doubleKey">0885-3185:1996:Metman L:effect:of:the</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8723141</idno><idno type="wicri:Area/PubMed/Corpus">004842</idno><idno type="wicri:Area/PubMed/Curation">004842</idno><idno type="wicri:Area/PubMed/Checkpoint">004834</idno><idno type="wicri:Area/Ncbi/Merge">004A93</idno><idno type="wicri:Area/Ncbi/Curation">004A93</idno><idno type="wicri:Area/Ncbi/Checkpoint">004A93</idno><idno type="wicri:doubleKey">0885-3185:1996:Metman L:effect:of:the</idno><idno type="wicri:Area/Main/Merge">008766</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:96-0244005</idno><idno type="wicri:Area/PascalFrancis/Corpus">003394</idno><idno type="wicri:Area/PascalFrancis/Curation">003430</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003377</idno><idno type="wicri:doubleKey">0885-3185:1996:Metman L:effect:of:the</idno><idno type="wicri:Area/Main/Merge">008909</idno><idno type="wicri:Area/Main/Curation">005660</idno><idno type="wicri:Area/Main/Exploration">005660</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease</title><author><name sortKey="Metman, L Verhagen" sort="Metman, L Verhagen" uniqKey="Metman L" first="L. Verhagen" last="Metman">L. Verhagen Metman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-05">1996-05</date><biblScope unit="vol">11</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="257">257</biblScope><biblScope unit="page" to="260">260</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">856FE7AA63A3BA4C2A33C0FBCD7FB272518A1A6D</idno><idno type="DOI">10.1002/mds.870110307</idno><idno type="ArticleID">MDS870110307</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Agonist</term><term>Antagonist</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Carbidopa (adverse effects)</term><term>Carbidopa (therapeutic use)</term><term>Chemotherapy</term><term>D1 Dopamine receptor</term><term>D1agonist</term><term>D2 Dopamine receptor</term><term>D2antagonist</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dopamine Antagonists (adverse effects)</term><term>Dopamine Antagonists (therapeutic use)</term><term>Dopamine D2 Receptor Antagonists</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Dyskinesias</term><term>Ergoline derivatives</term><term>Ergolines (adverse effects)</term><term>Ergolines (therapeutic use)</term><term>FCE 23884</term><term>Female</term><term>Human</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Receptors, Dopamine D1 (drug effects)</term><term>Receptors, Dopamine D1 (physiology)</term><term>Receptors, Dopamine D2 (physiology)</term><term>Treatment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Dopamine Antagonists</term><term>Ergolines</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Dopamine Agonists</term><term>Dopamine Antagonists</term><term>Ergolines</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dopamine D2 Receptor Antagonists</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Antagoniste</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Ergoline dérivé</term><term>FCE 23884</term><term>Homme</term><term>Parkinson maladie</term><term>Récepteur dopaminergique D1</term><term>Récepteur dopaminergique D2</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The ergoline derivative FCE 23884 acts as a dopamine D1 agonist in untreated parkinsonian animals and as a D2 antagonist in animals whose dopamine system is intact or levodopa treated. To evaluate whether this dual action might benefit patients with Parkinson's disease (PD) who have developed levodopa‐induced dyskinesias, the motor effects of FCE 23884 were examined in seven such individuals using a double‐blind, placebo‐controlled design. At doses up to the maximum tolerated dose (3.5 ± 0.5 mg), FCE 23884 monotherapy did not affect parkinsonian severity. On the other hand, coadministration of FCE 23884 with a mildly dyskinetic dose of levodopa, infused intravenously under steady‐state conditions, reduced the antiparkinson response by 54 ± 19% and tended to diminish dyskinesia severity. The results thus fail to suggest any useful role for FCE 23884 in the symptomatic treatment of PD. Although D2 receptor blockade provided by FCE 23884 antgonizes both the antiparkinson and dyskinesigenic responses to levodopa, the degree of D1 receptor stimulation appears insufficient to ameliorate parkinsonian symptomatology.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Metman, L Verhagen" sort="Metman, L Verhagen" uniqKey="Metman L" first="L. Verhagen" last="Metman">L. Verhagen Metman</name></region><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><name sortKey="De Jong, D" sort="De Jong, D" uniqKey="De Jong D" first="D." last="De Jong">D. De Jong</name><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005660 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005660 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:856FE7AA63A3BA4C2A33C0FBCD7FB272518A1A6D
|texte= Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |